Gov­ern­ment spend­ing bill tweak means 3 more NDAs will be­come BLAs, FDA says

As some in­sulin, hu­man growth hor­mone and oth­er prod­ucts tran­si­tion on 23 March from new drug ap­pli­ca­tions (NDAs) to bi­o­log­ics li­cense ap­pli­ca­tions (BLAs), the re­cent­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER